Glooko Inc. is thrilled to announce a partnering agreement with Sanofi US to better support people living with diabetes and healthcare professionals. The integration of SoloSmart with the Glooko® platform will allow patients to track their insulin dose, date and time of injection through a single piece add-on connected device that is compatible with SoloStar and DoubleStar insulin injection pens. Data can be easily shared with healthcare professionals for more connected care in diabetes management. Although SoloSmart is not currently approved in the US, this partnership will provide a more comprehensive approach to diabetes management.
Glooko’s global reach of over 8,000 clinics is about to get even bigger. Sanofi and Glooko have joined forces to provide people with diabetes more accessible digital solutions, starting with the SoloSmart cap. Later in 2023, their combined technology will become available in several countries, in both English and local languages. The agreement also opens up the possibility to expand the launch of the combined technologies beyond the initial countries.
We at Glooko are delighted to announce our partnership with Sanofi, which marks the first major collaboration between our two companies in the digital health space. As part of the agreement, Glooko will be launching its SoloSmart platform globally, enabling us to provide cutting-edge technologies to enhance the lives of those with diabetes. We are extremely proud to be taking this step forward, and are excited to see the positive results it will bring.
At Sanofi, we are committed to transforming diabetes care for the 537 million people living with the disease around the world. We are building an ecosystem of local and global partners, including Biocorp, SoloSmart’s manufacturer and Glooko, a leading digital health solution, to deliver value and improve daily management for individuals living with diabetes. For 100 years, Sanofi has been a pioneer in managing diabetes, and it remains our priority to continue our legacy and make a positive impact on lives.
SoloSmart and Glooko, when combined, offer users a powerful way to better manage their diabetes. By linking insulin dosing and timing data to Glooko’s features such as food tracking, exercise metrics, weight and blood pressure, individuals with diabetes can gain actionable insights that allow for a more personalized approach to care. With this integration, SoloStar and DoubleStar pen users will be able to visualize the correlation between insulin dose injected and blood glucose values to improve their overall diabetes management.
Glooko is revolutionizing chronic care with its personalized, intelligent, and connected platform. Our cutting-edge technologies are transforming how patients and providers interact, with digital therapeutics engaging patients and boosting adherence, and clinical trials accelerating at an unprecedented rate. Our platform is already being deployed in over 30 countries and 8,000+ clinical locations, helping to improve the health outcomes of people with chronic conditions around the world.